Potential immunotherapies for sarcoidosis

References

• Cozier YC. Assessing the worldwide epidemiology of sarcoidosis: challenges and future directions. Eur Respir J. 2016;48:1545–1548.
   PubMed Web of Science ®Google Scholar
• Judson MA. The clinical features of sarcoidosis: a comprehensive review. Clin Rev Allergy Immunol. 2015;49:63–78.
   PubMed Web of Science ®Google Scholar
• Drent M, Lower EE, De Vries J. Sarcoidosis-associated fatigue. Eur Respir J. 2012;40:255–263.
   PubMed Web of Science ®Google Scholar
• Goracci A, Fagiolini A, Martinucci M, et al. Quality of life, anxiety and depression in sarcoidosis. Gen Hosp Psychiatry. 2008;30:441–445.
   PubMed Web of Science ®Google Scholar
• Iannuzzi MC, Fontana JR. Sarcoidosis clinical presentation, immunopathogenesis, and therapeutics. Jama. 2011;305:391–399.
   PubMed Web of Science ®Google Scholar
• Zissel G, Muller-Quernheim J. Cellular players in the immunopathogenesis of sarcoidosis. Clin Chest Med. 2015;36:549–560.
   PubMed Web of Science ®Google Scholar
• Timmermans WM, Van Laar JA, Van Hagen PM, et al. Immunopathogenesis of granulomas in chronic autoinflammatory diseases. Clin Transl Immunol. 2016;5:e118.
   PubMed Web of Science ®Google Scholar
• Noor A, Knox KS. Immunopathogenesis of sarcoidosis. Clin Dermatol. 2007;25:250–258.
   PubMed Web of Science ®Google Scholar
• Ramstein J, Broos CE, Simpson LJ, et al. IFN-gamma-producing T-helper 17.1 cells are increased in sarcoidosis and are more prevalent than T-helper type 1 cells. Am J Respir Crit Care Med. 2016;193:1281–1291.
   PubMed Web of Science ®Google Scholar
• Mortaz E, Rezayat F, Amani D, et al. The roles of T helper 1, T helper 17 and regulatory T cells in the pathogenesis of sarcoidosis. Iran J Allergy Asthma Immunol. 2016;15:334–339.
   PubMed Web of Science ®Google Scholar
• Miyara M, Amoura Z, Parizot C, et al. The immune paradox of sarcoidosis and regulatory T cells. J Exp Med. 2006;203:359–370.
   PubMed Web of Science ®Google Scholar
• Taflin C, Miyara M, Nochy D, et al. FoxP3+ regulatory T cells suppress early stages of granuloma formation but have little impact on sarcoidosis lesions. Am J Pathol. 2009;174:497–508.
   PubMed Web of Science ®Google Scholar
• Moller M, Aries SP, Dromann D, et al. Intracellular cytokine repertoire in different T cell subsets from patients with sarcoidosis. Thorax. 2001;56:487–493.
   PubMed Web of Science ®Google Scholar
• Patterson KC, Hogarth K, Husain AN, et al. The clinical and immunologic features of pulmonary fibrosis in sarcoidosis. Transl Res. 2012;160:321–331.
   PubMed Web of Science ®Google Scholar
• Cox CE, Donohue JF, Brown CD, et al. Health-related quality of life of persons with sarcoidosis. Chest. 2004;125:997–1004.
   PubMed Web of Science ®Google Scholar
• Chen ES, Song Z, Willett MH, et al. Serum amyloid A regulates granulomatous inflammation in sarcoidosis through Toll-like receptor-2. Am J Respir Crit Care Med. 2010;181:360–373.
   PubMed Web of Science ®Google Scholar
• Herrtwich L, Nanda I, Evangelou K, et al. DNA damage signaling instructs polyploid macrophage fate in granulomas. Cell. 2016;167:1264–80 e18.
   PubMed Web of Science ®Google Scholar
• Montesinos MC, Desai A, Delano D, et al. Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. Arthritis Rheum. 2003;48:240–247.
   PubMed Web of Science ®Google Scholar
• Society AT. Statement on sarcoidosis. Am J Respir Crit Care Med. 1999;160:736–755.
   PubMed Web of Science ®Google Scholar
• Ferrante CJ, Pinhal-Enfield G, Elson G, et al. The adenosine-dependent angiogenic switch of macrophages to an M2-like phenotype is independent of interleukin-4 receptor alpha (IL-4Ralpha) signaling. Inflammation. 2013;36:921–931.
   PubMed Web of Science ®Google Scholar
• Hasko G, Cronstein B. Regulation of inflammation by adenosine. Front Immunol. 2013;4:85.
   PubMed Web of Science ®Google Scholar
• Isshiki T, Yamaguchi T, Yamada Y, et al. Usefulness of low-dose methotrexate monotherapy for treating sarcoidosis. Internal Medicine. 2013;52:2727–2732.
   PubMed Web of Science ®Google Scholar
• Lower EE, Baughman RP. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med. 1995;155:846–851.
   PubMedGoogle Scholar
• Chan ESL, Cronstein BN. Molecular action of methotrexate in inflammatory diseases. Arthritis Res. 2002;4:266–273.
   PubMedGoogle Scholar
• Maltzman JS, Koretzky GA. Azathioprine: old drug, new actions. J Clin Invest. 2003;111:1122–1124.
   PubMed Web of Science ®Google Scholar
• Poppe D, Tiede I, Fritz G, et al. Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins. J Immunol. 2005;176:640–651.
   Web of Science ®Google Scholar
• Muller-Quernheim J, Kienast K, Held M, et al. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J. 1999;14:1117–1122.
   PubMed Web of Science ®Google Scholar
• Vorselaars ADM, Wuyts WA, Vorselaars VMM, et al. Methotrexate vs azathioprine in second-line therapy of sarcoidosis. Chest. 2013;144:805–812.
   PubMed Web of Science ®Google Scholar
• Antoniu SA. Targeting the TNF-alpha pathway in sarcoidosis. Expert Opin Ther Targets. 2010;14:21–29.
   PubMed Web of Science ®Google Scholar
• Kreth S, Ledderose C, Luchting B, et al. Immunomodulatory properties of pentoxifylline are mediated via adenosine-dependent pathways. Shock. 2010;34:10–16.
   PubMed Web of Science ®Google Scholar
• Marques LJ, Zheng L, Poulaski N, et al. Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages. Am J Respir Crit Care Med. 1999;159:508–511.
   PubMed Web of Science ®Google Scholar
• Tong Z, Dai H, Chen B, et al. Inhibition of cytokine release from alveolar macrophages in pulmonary sarcoidosis by pentoxifylline. Chest. 2003;124:1526–1532.
   PubMed Web of Science ®Google Scholar
• Park MK, Fontana JR, Babaali H, et al. Steroid-sparing effects of pentoxifylline in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Disease. 2009;26:121–131.
   PubMed Web of Science ®Google Scholar
• Zabel P, Entzian P, Dalhoff K, et al. Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med. 1997;155:1665–1669.
   PubMed Web of Science ®Google Scholar
• Moreira AL, Sampaio EP, Zmuidzinas A, et al. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med. 1993;177:1675–1680.
   PubMed Web of Science ®Google Scholar
• Tavares JL, Wangoo A, Dilworth P, et al. Thalidomide reduces tumour necrosis factor-alpha production by human alveolar macrophages. Respir Med. 1997;91:31–39.
   PubMed Web of Science ®Google Scholar
• Droitcourt C, Rybojad M, Porcher R, et al. A randomized, investigator-masked, double-blind, placebo-controlled trial on thalidomide in severe cutaneous sarcoidosis. Chest. 2014;146:1046–1054.
   PubMed Web of Science ®Google Scholar
• Judson MA, Silvestri J, Hartung C, et al. The effect of thalidomide on corticosteroid-dependent pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Disease. 2006;23:51–57.
   PubMed Web of Science ®Google Scholar
• Fazzi P, Manni E, Cristofani R, et al. Thalidomide for improving cutaneous and pulmonary sarcoidosis in patients resistant or with contraindications to corticosteroids. Biomed Pharmacother. 2012;66:300–307.
   PubMed Web of Science ®Google Scholar
• Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83:1583–1590.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Judson MA, Ingledue R, et al. Efficacy and safety of apremilast in chronic cutaneous sarcoidosis. Arch Dermatol. 2012;148:262–264.
   PubMedGoogle Scholar
• Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006;174:795–802.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Judson MA, Lower EE, et al. Infliximab for chronic cutaneous sarcoidosis: a subset analysis from a double-blind randomized clinical trial. Sarcoidosis Vasc Diffuse Lung Disease. 2016;32:289–295.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Shipley R, Desai S, et al. Changes in chest roentgenogram of sarcoidosis patients during a clinical trial of infliximab therapy: comparison of different methods of evaluation. Chest. 2009;136:526–535.
   PubMed Web of Science ®Google Scholar
• Judson MA, Baughman RP, Costabel U, et al. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur Respir J. 2008;31:1189–1196.
   PubMed Web of Science ®Google Scholar
• Saleh S, Ghodsian S, Yakimova V, et al. Effectiveness of infliximab in treating selected patients with sarcoidosis. Respir Med. 2006;100:2053–2059.
   PubMed Web of Science ®Google Scholar
• Erckens RJ, Mostard RL, Wijnen PA, et al. Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol. 2012;250:713–720.
   PubMed Web of Science ®Google Scholar
• Milman N, Graudal N, Loft A, et al. Effect of the TNF-alpha inhibitor adalimumab in patients with recalcitrant sarcoidosis: a prospective observational study using FDG-PET. Clin Respir J. 2012;6:238–247.
   PubMed Web of Science ®Google Scholar
• Crommelin HA, van der Burg LM, Vorselaars AD, et al. Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab. Respir Med. 2016;115:72–77.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Lower EE, Bradley DA, et al. Etanercept for refractory ocular sarcoidosis. Chest. 2005;128:1062–1067.
   PubMed Web of Science ®Google Scholar
• Utz JP, Limper AH, Kalra S, et al. Etancercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest. 2003;124:177–185.
   PubMed Web of Science ®Google Scholar
• Amber KT, Bloom R, Mrowietz U, et al. TNF-alpha: a treatment target or cause of sarcoidosis? J Eur Acad Dermatol Venereol. 2015;29:2104–2111.
   PubMed Web of Science ®Google Scholar
• Judson MA, Baughman RP, Costabel U, et al. Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. Eur Respir J. 2014;44:1296–1307.
   PubMed Web of Science ®Google Scholar
• Takahashi R, Shijubo R, Shigehara K, et al. T helper 1 inhibitor TAK-603 inhibits IFN-gamma and IL-12 production with no effect on IL-18: an observation in sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Disease. 2004;21:204–211.
   PubMed Web of Science ®Google Scholar
• Alwan W, Nestle FO. Pathogenesis and treatment of psoriasis: exploiting pathophysiological pathways for precision medicine. Clin Exp Rheumatol. 2015;33:S2–S6.
   PubMed Web of Science ®Google Scholar
• Baumgart DC, Sandborn WJ. Crohn’s disease. The Lancet. 2012;380:1590–1605.
   PubMed Web of Science ®Google Scholar
• Reinisch W, De Villiers W, Bene L, et al. Fontolizumab in moderate to severe Crohn’s disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm Bowel Dis. 2010;16:233–242.
   PubMed Web of Science ®Google Scholar
• Harden JL, Johnson-Huang LM, Chamian MF, et al. Humanized anti-IFN-gamma (HuZAF) in the treatment of psoriasis. J Allergy Clin Immunol. 2015;135:553–556.
   PubMed Web of Science ®Google Scholar
• Sah BP, Goyal S, Iannuzzi MC. Novel pharmacotherapy of sarcoidosis. Pharmacol Ther. 2016;157:1–9.
   PubMed Web of Science ®Google Scholar
• Jiang Z, Zhu L. Update on the role of alternatively activated macrophages in asthma. J Asthma Allergy. 2016;9:101–107.
   PubMed Web of Science ®Google Scholar
• Liu YC, Zou XB, Chai YF, et al. Macrophage polarization in inflammatory diseases. Int J Biol Sci. 2014;10:520–529.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Sica A, Sozzani S, et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004;25:677–686.
   PubMed Web of Science ®Google Scholar
• Jiang H, Harris MB, Rothman P. IL-4/IL-13 signaling beyond JAK/STAT. J Allergy Clin Immunol. 2000;105:1063–1070.
   PubMed Web of Science ®Google Scholar
• Zeyda M, Poglitsch M, Geyeregger R, et al. Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin activation and immunologic synapse formation. Arthritis Rheum. 2005;52:2730–2739.
   PubMed Web of Science ®Google Scholar
• Siemasko K, Chong ASF, Jack HM, et al. Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production. J Immunol. 1998;160:1581–1588.
   PubMed Web of Science ®Google Scholar
• Sahoo DH, Bandyopadhyay D, Xu M, et al. Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. Eur Respir J. 2011;38:1145–1150.
   PubMed Web of Science ®Google Scholar
• He L, Marneros AG. Doxycycline inhibits polarization of macrophages to the proangiogenic M2-type and subsequent neovascularization. J Biol Chem. 2014;289:8019–8028.
   PubMed Web of Science ®Google Scholar
• Bachelez H, Senet P, Cadranel J, et al. The use of tetracyclines for the treatment of sarcoidosis. Arch Dermatol. 2001;137:69–73.
   PubMedGoogle Scholar
• Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375:2335–2348.
   PubMed Web of Science ®Google Scholar
• Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368:2455–2466.
   PubMed Web of Science ®Google Scholar
• Eishi Y, Suga M, Ishige I, et al. Quantitative analysis of mycobacterial and propionibacterial DNA in lymph nodes of Japanese and European patients with sarcoidosis. J Clin Microbiol. 2002;40:198–204.
   PubMed Web of Science ®Google Scholar
• Song Z, Marzilli L, Greenlee BM, et al. Mycobacterial catalase-peroxidase is a tissue antigen and target of the adaptive immune response in systemic sarcoidosis. J Exp Med. 2005;201:755–767.
   PubMed Web of Science ®Google Scholar
• Rotsinger JE, Celada LJ, Polosukhin VV, et al. Molecular analysis of sarcoidosis granulomas reveals antimicrobial targets. Am J Respir Cell Mol Biol. 2016;55:128–134.
   PubMed Web of Science ®Google Scholar
• Drake WP, Oswald-Richter K, Richmond BW, et al. Oral antimycobacterial therapy in chronic cutaneous sarcoidosis: a randomized, single-masked, placebo-controlled study. JAMA Dermatol. 2013;149:1040–1049.
   PubMed Web of Science ®Google Scholar
• Drake WP, Richmond BW, Oswald-Richter K, et al. Effects of broad-spectrum antimycobacterial therapy on chronic pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Disease. 2014;30:201–211.
   Web of Science ®Google Scholar
• Ungprasert P, Crowson CS, Matteson EL. Smoking, obesity and risk of sarcoidosis: a population-based nested case-control study. Respir Med. 2016;120:87–90.
   PubMed Web of Science ®Google Scholar
• Newman LS, Rose CS, Bresnitz EA, et al. A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am J Respir Crit Care Med. 2004;170:1324–1330.
   PubMed Web of Science ®Google Scholar
• Valeyre D, Soler P, Clerici C, et al. Smoking and pulmonary sarcoidosis: effect of cigarette smoking on prevalence, clinical manifestations, alveolitis, and evolution of the disease. Thorax. 1988;43:516–524.
   PubMed Web of Science ®Google Scholar
• Sugano N, Shimida K, Ito K, et al. Nicotine inhibits the prodiction of inflammatory mediators in U937 cells through modulation of nuclear factor-kB activation. Biochemal Biophys Res Commun. 1998;252:25–28.
   PubMed Web of Science ®Google Scholar
• Zheng YS, Wu ZS, Zhang LY, et al. Nicotine ameliorates experimental severe acute pancreatitis via enhancing immunoregulation of CD4+ CD25+ regulatory T cells. Pancreas. 2015;44:500–506.
   PubMed Web of Science ®Google Scholar
• Julian MW, Shao G, Schlesinger LS, et al. Nicotine treatment improves Toll-like receptor 2 and Toll-like receptor 9 responsiveness in active pulmonary sarcoidosis. Chest. 2013;143:461–470.
   PubMed Web of Science ®Google Scholar
• Salin-Pascual RJ, Rosas M, Jimenez-Genchi A, et al. Antidepressant effect of transdermal nicotine patches in nonsmoking patients with major depression. J Clin Psychiatry. 1996;57:387–389.
   PubMed Web of Science ®Google Scholar
• Warburton DM, Mancuso G. Evaluation of the information processing and mood effects of a transdermal nicotine patch. Psychopharmacology. 1998;135:305–310.
   PubMed Web of Science ®Google Scholar
• Le Houezec J, Halliday R, Benowitz NL, et al. A low dose of subcutaneous nicotine improves information processing in non-smokers. Psychopharmacology. 1994;114:628–634.
   PubMed Web of Science ®Google Scholar
• Gentry MV, Hammersley JJ, Hale CR, et al. Nicotine patches improve mood and response speed in a lexical decision task. Addict Behav. 2000;25:549–557.
   PubMed Web of Science ®Google Scholar
• Braun NA, Celada LJ, Herazo-Maya JD, et al. Blockade of the programmed death-1 pathway restores sarcoidosis CD4(+) T-cell proliferative capacity. Am J Respir Crit Care Med. 2014;190:560–571.
   PubMed Web of Science ®Google Scholar
• Celada LJ, Rotsinger JE, Young A, et al. Programmed death-1 inhibition of phosphatidylinositol 3-kinase/AKT/mechanistic target of rapamycin signaling impairs sarcoidosis CD4(+) T cell proliferation. Am J Respir Cell Mol Biol. 2017;56:74–82.
   PubMed Web of Science ®Google Scholar
• Broos CE, van Nimwegen M, Kleinjan A, et al. Impaired survival of regulatory T cells in pulmonary sarcoidosis. Respir Res. 2015;16:108.
   PubMed Web of Science ®Google Scholar
• Broos CE, Veen JC, Hoogsteden HC. Decreased cytotoxic T-Lymphocyte antigen 4 expression on regulatory T cells and Th17 cells in sarcoidosis: double trouble? Am J Respir Crit Care Med. 2015;192:763–765.
   PubMed Web of Science ®Google Scholar
• Lomax AJ, McGuire HM, McNeil C, et al. Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: case series and immunophenotypic analysis. Int J Rheum Dis. 2017;20:1277–1285.
   PubMed Web of Science ®Google Scholar
• Reddy SB, Possick JD, Kluger HM, et al. Sarcoidosis AA-PD-1 and anti-CTLA-4 therapy for metastatic melanoma. J Immunother. 2017;40:307–311.
   PubMed Web of Science ®Google Scholar
• Cousin S, Italiano A. Pulmonary sarcoidosis or post-immunotherapy granulomatous reaction induced by the anti-PD-1 monoclonal antibody pembrolizumab: the termilogy is not the key point. Ann Oncol. 2016;27:1974–1975.
   PubMed Web of Science ®Google Scholar
• Kamphuis LS, Van Zelm MC, Lam KH, et al. Perigranuloma localization and abnormal maturation of B cells: emerging key players in sarcoidosis? Am J Respir Crit Care Med. 2013;187:406–416.
   PubMed Web of Science ®Google Scholar
• Lee NS, Barber L, Akula SM, et al. Disturbed homeostasis and multiple signaling defects in the peripheral blood B-cell compartment of patients with severe chronic sarcoidosis. Clin Vaccine Immunol. 2011;18:1306–1316.
   PubMed Web of Science ®Google Scholar
• Saussine A, Tazi A, Feuillet S, et al. Active chronic sarcoidosis is characterized by increased transitional blood B cells, increased IL-10-producing regulatory B cells and high BAFF levels. PLoS One. 2012;7:e43588.
   PubMed Web of Science ®Google Scholar
• Ueda-Hayakawa I, Tanimura H, Osawa M, et al. Elevated serum BAFF levels in patients with sarcoidosis: association with disease activity. Rheumatology (Oxford). 2013;52:1658–1666.
   PubMed Web of Science ®Google Scholar
• Sweiss NJ, Lower EE, Mirsaedi M, et al. Rituximan in the treatment of refractory pulmonary sarcoidosis. Eur Respir J. 2014;43:1525–1528.
   PubMed Web of Science ®Google Scholar
• Hao W, Crouser ED, Friedman A. Mathematical model of sarcoidosis. Proc Natl Acad Sci U S A. 2014;111:16065–16070.
   PubMed Web of Science ®Google Scholar
• Crouser ED, White P, Caceres EG, et al. A novel in vitro human granuloma model of sarcoidosis and latent tuberculosis infection. Am J Respir Cell Mol Biol. 2017;57:487–498.
   PubMed Web of Science ®Google Scholar
• Maier LA, Crouser ED, Martin WJ, et al. Executive summary of the NHLBI workshop report: leveraging current scientific advances to better understand sarcoidosis variability and improve outcome. Ann Am Thorac Soc. 2017 Oct 19. Epub ahead of print. DOI:10.1513/AnnalsATS.201707-563OT
   Web of Science ®Google Scholar
• Crouser ED, Fingerlin TE, Yang IV, et al. Application of ‘Omics’ and systems biology to sarcoidosis research. Ann Am Thorac Soc. 2017 Oct 20. Epub ahead of press. DOI:10.1513/AnnalsATS.201707-567OT
   Web of Science ®Google Scholar
• Abrahamyan L, Feldman BM, Tomlinson G, et al. Alternative designs for clinical trials in rare diseases. Am J Med Genet C Semin Med Genet. 2016;172:313–331.
   PubMed Web of Science ®Google Scholar